Department of Health Sciences, Oita University of Nursing and Health Sciences , Oita , Japan .
Immunopharmacol Immunotoxicol. 2014 Feb;36(1):61-9. doi: 10.3109/08923973.2013.866678. Epub 2013 Dec 16.
Subcutaneous injection of low dose of phthalates causes adjuvant effects on immunoglobulin production. Moreover, intraperitoneal injection of di-(2-ethylhexyl) phthalate (DEHP) and diisononyl phthalate (DINP) at doses lower than the no-observed-adverse-effect level (NOAEL) causes aggravation of atopic dermatitis-like skin lesions (ADSLs) in mouse models. However, the effects of oral exposure to these phthalates, including their effect on atopic dermatitis (AD) symptoms, remain unclear.
To investigate the effects of oral administration of DEHP and DINP at doses lower than the NOAEL on AD in an NC/Nga mouse model.
NC/Nga mice were subcutaneously injected with mite-allergen (Dermatophagoides pteronyssinus) to induce ADSLs and orally administered varying doses of DEHP (0, 8.3, 166.3 or 3325 µg/animal) or DINP (0, 6.6, 131.3 or 2625 µg/animal) once a week for four weeks. Skin disease symptomatology was subsequently evaluated and immunoglobulin production levels in serum and inflammatory cytokine levels in lesion sites were measured.
Oral administration of low doses of both DEHP and DINP tended to increase infiltration of eosinophils; degranulation of mast cells and local expression of inflammatory cytokines, interleukin-13 and macrophage inflammatory protein-1 alpha in subcutaneous tissue, whereas DINP administration tended to aggravate allergen-induced ADSL production.
Oral administration of both DEHP and DINP at doses lower than the NOAEL tends to increase the allergic response in animal AD models, but only DINP administration slightly aggravates allergen-induced ADSL production.
低剂量邻苯二甲酸酯的皮下注射会对免疫球蛋白的产生产生佐剂作用。此外,低于无观察到不良效应水平(NOAEL)的剂量的二-(2-乙基己基)邻苯二甲酸酯(DEHP)和二异壬基邻苯二甲酸酯(DINP)的腹腔内注射会导致小鼠模型中特应性皮炎样皮肤损伤(ADSL)的加重。然而,这些邻苯二甲酸酯的口服暴露的影响,包括它们对特应性皮炎(AD)症状的影响,尚不清楚。
研究低于 NOAEL 的 DEHP 和 DINP 口服剂量对 NC/Nga 小鼠模型中 AD 的影响。
NC/Nga 小鼠被皮下注射螨过敏原(粉尘螨)以诱导 ADSL,并每周口服不同剂量的 DEHP(0、8.3、166.3 或 3325µg/动物)或 DINP(0、6.6、131.3 或 2625µg/动物)一次,共四周。随后评估皮肤疾病症状,并测量血清中的免疫球蛋白水平和病变部位的炎症细胞因子水平。
口服低剂量的 DEHP 和 DINP 均倾向于增加嗜酸性粒细胞的浸润;肥大细胞脱颗粒和皮下组织中炎症细胞因子白细胞介素-13 和巨噬细胞炎症蛋白-1α的局部表达,而 DINP 给药则倾向于加重过敏原诱导的 ADSL 产生。
低于 NOAEL 的 DEHP 和 DINP 口服剂量均倾向于增加动物 AD 模型中的过敏反应,但仅 DINP 给药略微加重过敏原诱导的 ADSL 产生。